IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Superior execution in consumer wellness/exports drives beat on 2Q estimates Integration of BSV under way * Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business. * MANKIND continues to deliver a better growth rate than the industry in the Rx-prescription business, supported by a niche portfolio and superior execution in chronic therapies....
Buy Mankind Pharma Ltd For Target Rs.3,140 By Motilal Oswal Financial Services Ltd
Mankind Pharma on Wednesday said it has completed the acquisition of Bharat Serums and Vaccines Limited (BSV) for Rs 13,768 crore. The acquisition will position Mankind Pharma as a market leader in the Indian women's health and fertility drug market, alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms, it said in a statement. Their established specialty R&D tech platforms with complex portfo...
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore
Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strateg...
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strat...
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strat...
Buy Mankind Pharma Ltd Target Rs.2,760 By Motilal Oswal Financial Services Ltd
Improvising the base; adding new avenues for growth * Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report. * MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-thecounter (OTC) space. * During FY22-24, its strateg...
Buy Mankind Pharma Ltd For Target Rs. 2,760 By Motilal Oswal Financial Services Ltd
Riding on overall economic growth, Indian startups raised more than $395 million in at least 20 deals this week, a massive about 350 per cent jump from $113 million secured last week in 22 deals. Hospitality and travel-tech company Oyo led the funding ecosystem with raising Rs 1,457 crore (nearly $175 million) in a Series G round from investors like InCred Wealth, Patient Capital, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings, am...
Indian startups secure $395 million this week, a massive 350 pc jump
Unlocking new vertical through BSV acquisition Aim to be EPS-accretive from second year after deal closure * Mankind Pharma has agreed to acquire Bharat Serum Vaccines (BSV) for EV of INR136b, implying EV/EBITDA of 28x/22-23x on FY24/FY25 basis. * This acquisition not only expands Mankind’s niche portfolio, but also provides a specialty R&D tech platform, in-house complex manufacturing capabilities and strong institutional reach. * Considering access to a high-entry barr...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Disruptor with a dose of care * In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic formulation (DF) franchise and become the fourth largest player by market share. * Contrary to common wisdom, MANKIND has followed a disruptive strategy to establish its DF business by approaching customers and influencers in tier II and below cities, becoming the industry leader in terms of the number of prescriptions. * It has diversified its portfolio in terms of both therap...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Disruptor with a dose of care * In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic formulation (DF) franchise and become the fourth largest player by market share. * Contrary to common wisdom, MANKIND has followed a disruptive strategy to establish its DF business by approaching customers and influencers in tier II and below cities, becoming the industry leader in terms of the number of prescriptions. * It has diversified its portfolio in terms of both thera...
Buy Mankind Pharma Ltd For Target Rs.2,650 By Motilal Oswal Financial Services
Indian pharmaceutical company Mankind Pharma posted a more than 65% rise in its fourth-quarter profit on Wednesday, helped by strong domestic demand in its chronic drugs segment. The company also approved a fundraise of up to 75 billion rupees or an equivalent amount via issuance of shares under qualified institutional placement, it said in an exchange filing. Mankind, which makes acute and chronic therapeutics, including anti-infectives and anti-diabetics, posted consolidated profit at...
India`s Mankind Pharma`s Q4 profit jumps on strength in chronic drugs segment
Overall public equity fundraising increased by a huge 142 per cent to Rs 1.86 lakh crore in 2023-24 from Rs 76,911 crore in 2022-23. Pranav Haldea, Managing Director, Prime Database, said 76 Indian corporates raised Rs 61,915 crore through main board IPOs in financial year 2023-24, 19 per cent higher than the Rs 52,116 crore mobilised by 37 IPOs in 2022-23. The largest IPO in 2023-24 was from Mankind Pharma (Rs 4,326 crore). This was followed by Tata Technologies (Rs 3,043 crore) and JS...
Public equity fundraising increased by a huge 142 pc to Rs 1.86 lakh crore
Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or 0.15% from its previous closing of Rs. 2162.30 on the BSE. The scrip opened at Rs. 2156.80 and has touched a high and low of Rs. 2195.95 and Rs. 2154.60 respectively. So far 1732 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2297.00 on 08-Feb-2024 and a 52 week low of Rs. 1240.75 on 22-May-2023. Last one week high and low of the scrip sto...
Mankind Pharma inches up on inking pact with AstraZeneca Pharma India
Mankind Pharma is currently trading at Rs. 1895.00, up by 7.20 points or 0.38% from its previous closing of Rs. 1887.80 on the BSE. The scrip opened at Rs. 1925.60 and has touched a high and low of Rs. 1925.60 and Rs. 1886.00 respectively. So far 3933 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2039.95 on 21-Nov-2023 and a 52 week low of Rs. 1240.75 on 22-May-2023. Last one week high and low of the scrip sto...
Mankind Pharma rises on making investment in Actimed Therapeutics
Load More
